SCHEDULE: Adage Capital Discloses 9.88% Stake in EyePoint
Beneficial Ownership Disclosure
Adage Capital Management, L.P. and its principals reported a 9.88% beneficial ownership stake in EyePoint Pharmaceuticals, Inc. as of June 30, 2025.
Summary
- Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, collectively reported beneficial ownership of 6,800,000 shares of EyePoint Pharmaceuticals, Inc. Common Stock.
- This ownership represents 9.88% of the company's outstanding Common Stock.
- The percentage is calculated based on 68,811,736 shares of Common Stock outstanding as of May 1, 2025, as reported in EyePoint's Quarterly Report on Form 10-Q filed on May 8, 2025.
- The reporting persons hold shared voting power and shared dispositive power over all 6,800,000 shares.
- The filing is an Amendment No. 4 to a Schedule 13G, indicating an update to a previously disclosed position.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The filing is a neutral disclosure of beneficial ownership, indicating a significant institutional stake without providing performance or operational updates.
Positives
- Adage Capital Management, L.P. and its principals reported a significant beneficial ownership of 9.88% in EyePoint Pharmaceuticals, Inc.
- The investment is stated to be held in the ordinary course of business, indicating a passive investment intent rather than an attempt to influence or change control of the issuer.
Industry Context
This filing indicates continued institutional interest in EyePoint Pharmaceuticals, a company operating in the biotechnology/pharmaceutical sector. Large institutional holdings like this are common for companies with promising drug pipelines or market positions, signaling investor confidence in the company's long-term prospects.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and liquidity.
- Company Management: Awareness of a large, passive institutional investor on their shareholder register.
Key Dates
| Date | Description |
|---|---|
| 2025-05-01 | Date of shares outstanding calculation (68,811,736 shares) as reported in the Company's Form 10-Q. |
| 2025-05-08 | Date EyePoint Pharmaceuticals, Inc. filed its Quarterly Report on Form 10-Q for the period ended March 31, 2025. |
| 2025-06-30 | Date of event which requires filing of this statement. |
| 2025-08-12 | Date of filing of this Schedule 13G Amendment No. 4. |
Keywords
EyePoint Pharmaceuticals, Adage Capital Management, Institutional Ownership, Common Stock, SEC Filing, Schedule 13G, Biotechnology, Pharmaceuticals, Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.